Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 15;25(20):11091.
doi: 10.3390/ijms252011091.

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges

Alessandro Rizzo  1 , Oronzo Brunetti  1 , Giovanni Brandi  2   3
Affiliations
Review

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges

Alessandro Rizzo et al. Int J Mol Sci. .

Abstract

Immune checkpoint inhibitors (ICIs), such as durvalumab, tremelimumab, and atezolizumab, have emerged as a significant therapeutic option for the treatment of hepatocellular carcinoma (HCC). In fact, the efficacy of ICIs as single agents or as part of combination therapies has been demonstrated in practice-changing phase III clinical trials. However, ICIs confront several difficulties, including the lack of predictive biomarkers, primary and secondary drug resistance, and treatment-related side effects. Herein, we provide an overview of current issues and future challenges in this setting.

Keywords: PD-L1; cancer; hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; liver cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Pro- and anti-tumor cells in the tumor microenvironment.
Figure 2
Figure 2
Immunotherapies in hepatocellular carcinoma patients.
See this image and copyright information in PMC

References

    1. Benson A.B., D’Angelica M.I., Abbott D.E., Anaya D.A., Anders R., Are C., Bachini M., Borad M., Brown D., Burgoyne A., et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2021;19:541–565. doi: 10.6004/jnccn.2021.0022. - DOI - PubMed
    1. Rizzo A., Ricci A.D., Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: Tempted to do something rather than nothing. Future Oncol. 2020;16:2587–2589. doi: 10.2217/fon-2020-0669. - DOI - PubMed
    1. Ayuso C., Rimola J., Vilana R., Burrel M., Darnell A., García-Criado Á., Bianchi L., Belmonte E., Caparroz C., Barrufet M., et al. Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines. Eur. J. Radiol. 2018;101:72–81. doi: 10.1016/j.ejrad.2018.01.025. Erratum in Eur. J. Radiol. 2019, 112, 229. https://doi.org/10.1016/j.ejrad.2019.01.018 . - DOI - PubMed
    1. Wen N., Cai Y., Li F., Ye H., Tang W., Song P., Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci. Trends. 2022;16:20–30. doi: 10.5582/bst.2022.01061. - DOI - PubMed
    1. Vogel A., Martinelli E., ESMO Guidelines Committee Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann. Oncol. 2021;32:801–805. doi: 10.1016/j.annonc.2021.02.014. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources